Archives: Press Releases

New Haven, Conn., January 9, 2020 – Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced CBX-12 (alphalex^TM-exatecan) as the new lead development program. CBX-12 is an alphalex^TM conjugate that includes the highly potent topoisomerase I inhibitor exatecan.

CBX-12 has demonstrated strong efficacy and a solid safety profile in preclinical studies.  CBX-12 leverages the same class of payload used in the antibody-drug conjugate (ADC) ENHERTU® (fam-trastuzumab deruxtecan-nxki), which was recently approved by the U.S. Food and Drug Administration under Accelerated Approval in unresectable or metastatic HER2-positive breast cancer. Like ENHERTU®, CBX-12 delivers a highly potent topoisomerase I payload, but CBX-12 targets tumors without the need for a specific antigen and therefore has the potential to address a much broader patient population. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021.

Per Hellsund, President and CEO of Cybrexa said, “CBX-12 has tremendous potential to change the treatment paradigm in multiple solid tumors, which remain hard to treat.  We are committed to moving this program rapidly into the clinic, and ultimately benefit as many patients as possible.  We look forward to reporting on CBX-12’s progress at upcoming high-profile medical conferences in 2020.”

Chief Scientific Officer Vishwas Paralkar, PhD, added, “The CBX-12 program has shown outstanding results in preclinical studies and showcases the potential and opportunity for the alphalex^TM platform. We continue to make good progress with our other programs in the preclinical pipeline and look forward to advancing those candidates as we work to provide treatments to as many patients as possible.”

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent (payload) – enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care.  pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces.  pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.  alphalex™ represents the disruptive next generation in tumor targeting.  View a video of the mechanism of action of the technology at www.cybrexa.com.   

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs.  Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit www.cybrexa.com.

Media Contact

Amanda Johnson

Phone: 202.930.4762 x407

Email: [email protected]

 

New Haven, Conn., December 9, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the Company is expanding the application of its proprietary alphalex™ platform to include toxin conjugates and additional next generation synthetic lethality targets.

Two of Cybrexa’s new preclinical pipeline programs include CBX-12 (alphalex^TM-exatecan) and CBX-13 (alphalex^TM-DM4).  Both exatecan and DM4 are highly toxic to cells and require targeted delivery to be used as cancer therapies, making them prime opportunities for the alphalex^TM platform.  Both programs are expected to have efficacy across a variety of solid tumors.  Preclinical work is ongoing, with publication of initial data expected by mid-2020.

Per Hellsund, President and CEO of Cybrexa said, “We are excited to broaden the application of our alphalex^TM technology platform to expand our pipeline. We have made rapid progress with our new programs and believe these agents could be transformative both in patient populations where few treatment options or remaining unmet needs exist. We look forward to continuing to explore new applications of alphalex^TM to bring benefits to patients.”

Scientific Co-founder Peter Glazer, MD, PhD, commented on CBX-12, “Our early preclinical data shows very impressive efficacy in mouse tumor models with essentially no toxicity, quite unlike the situation that you see with the free molecule [exatecan].  We believe that this will provide the needed therapeutic index to apply the Cybrexa technology with exatecan to a variety of human solid tumors.”

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces.  pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.  View a video of the mechanism of action of the technology at www.cybrexa.com.

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor conjugate, is expected to enter Phase I in 2020 in advanced solid tumors. Cybrexa also has preclinical programs focused on next-generation synthetic lethality targets and toxin conjugates.  Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

Media Contact

Amanda Johnson

Phone: 202.930.4762 x407

Email: [email protected]

John Houston brings more than 30 years of experience in drug discovery and development in pharma and biotech as Cybrexa prepares to transition to become a clinical-stage company

New Haven, Conn., September 3, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today announced the appointment of John Houston, PhD, to its board of directors. Dr. Houston brings more than 30 years of biotech and pharma drug development and management experience, including serving as the current CEO of Arvinas, Inc., a publicly traded targeted protein degradation biotech with programs in Oncology and Neuroscience.

 

“John has established an incredible reputation and track record in leading companies to successfully and quickly bring innovative drugs to patients,” said Per Hellsund, President and CEO of Cybrexa. “We are delighted that John will be joining the Cybrexa board at this point in time.  Cybrexa is on the cusp of entering the clinic with our lead candidate, CBX-11 (alphalex^TM-rucaparib), and substantially expanding our pipeline.  John’s experience in oncology and guiding companies through the transition from preclinical- to clinical-stage and private to public will be extremely valuable as Cybrexa continues to grow.”

 

Dr. Houston is President and Chief Executive Officer of Arvinas, Inc. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. He was also the site head of the BMS Connecticut facility. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials, and toward commercialization.  Dr. Houston has over 30 years of experience in the pharmaceutical and biotech industry. Prior to joining Bristol-Myers Squibb, he worked at Glaxo Wellcome Research and Development in the UK, where he served as head of the Lead Discovery Unit.

 

Dr. Houston obtained his B.Sc degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.

 

“I believe Cybrexa’s alphalex^TM technology platform has tremendous potential to efficiently bring new treatment options to patients by leveraging already identified anti-cancer agents that have prohibitive toxicity profiles but promising potential efficacy” said Dr. Houston.  “I am excited to be joining the Cybrexa board and look forward to working with the leadership team to provide my insights about the further development of CBX-11 and other alphalex-conjugates for cancer patients with high unmet need”

 

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at www.cybrexa.com.

 

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 

Media Contact

[email protected]

New Haven, Conn., July 2, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the company has been awarded a Fast Track Small Business Innovation Research (SBIR) Grant from the National Institute of Health (NIH). This award will support the development of the company’s lead candidate, CBX-11, Cybrexa’s proprietary alphalex™ technology combined with the already-approved oral small molecule poly ADP-ribose polymerase (PARP) inhibitor rucaparib, in combination with chemotherapy.

Per Hellsund, President and Chief Executive Officer of Cybrexa Therapeutics, stated, “We are extremely grateful to the NIH for this grant, the recognition of our science, and the importance of advancing the development of our new class of small molecule DNA repair inhibitors and DNA-damaging agents. In particular, this NIH grant will aid Cybrexa’s development of lead candidate, CBX-11, which we plan to enter into the clinic in the first quarter of next year. CBX-11 has the potential to enable effective treatment of tumors that are not homologous recombination deficient in combination with DNA-damaging chemotherapy agents.”

 

Ranjit Bindra, Cybrexa scientific co-founder and collaborator on the proposal, added, “It’s quite exciting to see that our technology has been favorably peer-reviewed from a scientific standpoint, gaining traction with acceptances for presentation at medical meetings, and is now being supported by a highly competitive grant award program such as the SBIR.  This SBIR grant represents an important external validation of the core technology that Cybrexa is developing.”

 

About National Institute of Health (NIH) and Small Business Innovation Research

NIH Small Business Innovation Research (SBIR) is one of the largest sources of early-stage capital for technology commercialization in the United States and enables small businesses to engage in federal research and development of innovative biomedical technologies with a strong potential for commercialization. In FY2018, NIH’s SBIR and STTR programs will invest over 1 billion dollars into health and life science companies that are creating innovative technologies that align with NIH’s mission to improve health and save lives.

 

About Poly (ADP-ribosome) polymerase (PARP) inhibitors in Combination with Chemotherapy

Poly (ADP-ribosome) polymerase (PARP) inhibitors have demonstrated clear efficacy as monotherapies in the clinic against metastatic solid tumors in cancers with homologous recombination deficiency (HRD). PARP inhibitors have showed only limited activity against non-HRD cancers. Combination therapy with DNA-damaging chemotherapy agents has the potential to greatly enhance anti-tumor activity in non-HRD cancers, but combining PARP inhibitors with chemotherapy in clinical studies has been challenging largely due to the accompanying toxicity.

 

About alphalex^TM   Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 

Contacts

Media Relations

[email protected]

New Haven, Conn., June 20, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced the completion of a $13.4 million Series B1 financing.

This brings the company’s total capital raised to date to $21.1 million. Cybrexa’s existing investors – CT Innovations, HighCape Capital Special Opportunities Fund, and Cycle Venture Partners – all participated in the round. Proceeds from the financing will be used to advance Cybrexa’s first clinical candidate CBX-11 (alphalex^TM-rucaparib) into clinical development and to progress additional programs in its preclinical pipeline.

“This level of financial support from our investors demonstrates the continued enthusiasm and validation for our innovative, proprietary alphalex™ platform technology,” said Per Hellsund, President & CEO of Cybrexa. “We look forward to advancing our lead candidate, CBX-11, into the clinic by the first quarter of 2020 as well as further developing additional new therapeutic candidates leveraging our alphalex™ technology, which we believe has the transformative potential to improve tumor response and overall survival while limiting toxicity.”

 

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 

Contacts

Media Relations

[email protected]

Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Results support the potential of alphalex™ technology with diverse range of anticancer agents

Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP inhibitors are combined with chemotherapy

New Haven, Conn., May 15, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced preclinical data supporting the potential of its proprietary alphalex™ technology platform. Results from multiple preclinical studies demonstrate that alphalex™ successfully enables the combination of a diverse range of structurally unique PARP inhibitors with DNA damaging chemotherapies in doses that effectively induce significant tumor cell killing, representing a new approach to target homologous recombination deficiency (HRD)-negative cancers without causing significant bone marrow toxicity.

The studies showed that each of the alphalex™-PARP inhibitor conjugated molecules was successfully delivered to tumor cells while sparing other tissues. Researchers observed significant reductions in PARylation activity and strong synergy with DNA damaging agents in vitro. Researchers then demonstrated that alphalex™-PARP inhibitor conjugates in combination with both temozolomide and irinotecan induced significant tumor cell killing in HRD-negative tumors in vivo. Importantly, they found that the alphalex™ tumor-targeting approach significantly reduced normal tissue toxicity, with almost complete sparing of the bone marrow relative to temozolomide alone.

“Cybrexa’s unique alphalex™ platform enables multiple PARP inhibitor combinations with clinically-relevant chemotherapies, providing a new way to target HRD-negative cancers without significant bone marrow toxicity,” said Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa. “Based on these successful proof-of-concept data, we are now performing IND-enabling studies for our lead program, CBX-11 (alphalex-rucaparib), and plan to initiate our first Phase I clinical trial in the first quarter of 2020 in solid tumors independent of HRD status. This is the first of several programs we plan to bring to the clinic that have the ability to leverage the efficacy of known potent anticancer agents without inducing associated toxicities.”

The data were published in an online only abstract, titled “Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex™ tumor targeting platform,” accepted by the American Society for Clinical Oncology (ASCO) Annual Meeting 2019.

https://abstracts.asco.org/239/AbstView_239_267983.html

About the alphalex™ Technology Platform

 

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

 

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 

Contacts

Media Relations

[email protected]

New Haven, Conn., May 8, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Per Hellsund, President and Chief Executive Officer of the Company, will present at the 2019 BIO International Convention being held on June 3-6, 2019 at the Pennsylvania Convention Center in Philadelphia, PA.

Mr. Hellsund will present a corporate overview on the Company’s platform, pipeline, and lead candidate CBX-11 (alphalex^TM-rucaparib)

Details for the presentation are below:

Event: 2019 BIO International Convention

Date: Monday, June 3, 2019

Time: 2:45 pm ET

Location: Pennsylvania Convention Center, Theatre 4

 

Members of the management team will be available for meetings at the BIO International Convention in Philadelphia. To arrange a meeting with management, please contact Janhavi Mohite at [email protected] or visit the BIO One-on-One Partnering webpage to schedule a meeting directly.

 

About the alphalex™ Technology Platform

 

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

 

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 Contacts

Media Relations

[email protected]

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors  

Poster presentation today during AACR Annual Meeting 2019

New Haven, Conn., April 2, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The first set of preclinical data supporting CBX-11 demonstrate that Cybrexa’s proprietary alphalex™ platform can enable full dose administration with DNA damaging chemotherapy, creating synergistic efficacy in destroying solid tumors independent of homologous recombination deficiency (HRD) status. In particular, CBX-11 selectively delivers rucaparib to tumor tissue, avoiding the bone marrow toxicity that has prevented optimal dosing of DNA damaging chemotherapy in combination with PARP inhibitors.

These data were exhibited today in a poster presentation by Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, during the American Association for Cancer Research (AACR) Annual Meeting 2019.

“These mark the first results demonstrating that combination of the potent PARP inhibitor rucaparib and chemotherapy is able to effectively kill cancer cells independent of HRD status and without the extreme bone marrow toxicity historically observed in this combination, which previously resulted in significant dose reduction and therefore efficacy reduction,” said Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa. “The synergistic efficacy allowing full dose administration of both rucaparib and chemotherapy is a direct result of our alphalex™ technology platform that selectively targets tumor cells to overcome this barrier for combination therapies.”

In the study, tumor targeting of rucaparib was achieved using the alphalex™ platform, which allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment. These data demonstrate that the alphalex™ conjugate inserts only across cancer cell membranes to deliver its cargo directly into the cancer cell.  The safety and efficacy of the approach was confirmed in vivo using CBX-11, which was safely administered with cytotoxic chemotherapies to selectively kill both HRD-positive and HRD-negative tumors with significant sparing of bone marrow.

Per Hellsund, President and CEO of Cybrexa, commented, “These preclinical results highlight an entirely new approach to applying PARP inhibitors against solid tumors independent of HRD status and directly support our Phase 1 clinical trial evaluating CBX-11 in combination with chemotherapy, which is planned to start in the first quarter of 2020. Furthermore, our alphalex™ platform approach can be applied to a diverse range of DNA damage repair inhibitors to enable combinations with chemotherapy and chemo-radiation in a tissue-agnostic manner and we look forward to discussing these applications.”

Link to poster: https://www.cybrexa.com/wp-content/uploads/2019/04/Cybrexa-Poster-2981-AACR-Mtg-Atlanta-Mar2019-002.pdf

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-rucaparib combination, is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

Contacts

Media Relations

[email protected]

New Haven, Conn., March 18, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.

 

CBX-11 combines Cybrexa’s proprietary alphalex™ tumor targeting technology with an already-approved oral small molecule PARP inhibitor. CBX-11 will be evaluated in combination with DNA damaging chemotherapy for the treatment of patients with solid tumors that lack homologous recombination deficiency (HRD). The company remains on track to submit its Investigational New Drug (IND) application for CBX-11 by the fourth quarter of 2019, with a Phase 1 clinical trial evaluating CBX-11 in combination with chemotherapy anticipated to begin in the first quarter of 2020.

 

Details for the poster presentation are as follows:

 

Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor

Permanent Abstract # 2981 / Poster #3

Session: Diagnostics, Biomarkers, and the Tumor Microenvironment

Date and Time: Tuesday, April 2; 8:00 am – 12:00 pm EST

Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 11

Presenting Author: Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa

 

“This marks the first set of preclinical data supporting our lead candidate CBX-11, which we formally announced at the beginning of the year,” said Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa. “Our alphalex™ tumor targeting technology represents a novel approach to enable the synergistic efficacy of a PARP inhibitor and chemotherapy administered at full dose. We are excited to share these compelling data and take the opportunity to unveil the composition of CBX-11, especially given the current development landscape and high profile of PARP inhibitors.”

 

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology.

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 

Contacts

Media Relations

[email protected]

 

Cybrexa Therapeutics Announces Multiple Oral Presentations Highlighting the Advances in the Application of DNA Repair Pathways in Cancer Drug Development at the DNA Damage Response Therapeutics Summit 2019

New Haven, Conn., January 22, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today announced that Dr. Vishwas Paralkar, Chief Scientific Officer of Cybrexa, and Dr. Ranjit Bindra, Cybrexa Scientific Co-founder and Associate Professor at the Yale School of Medicine, will deliver presentations as expert speakers showcasing the advancement of DNA repair pathways in the field of cancer therapeutics. The presentations will be made at the upcoming Cybrexa Therapeutics Announces Multiple Oral Presentations Highlighting the Advances in the Application of DNA Repair Pathways in Cancer Drug Development at the DNA Damage Response Therapeutics Summit 2019 being held January 29-31, 2019 in Boston, MA.

Details of the presentations include:

• PARP Inhibitors in the New Era, New Targets & New Targeting Techniques

Presenter:           Dr. Vishwas Paralkar

Session:               New Developments in PARP Inhibitors & Novel DDR Pathway Targets

Date/Time:         Wednesday, January 30^th from 2:30 – 3:00 p.m. EST

• Discovery of IDH1/2 Mutations Which Induce a BRCAness State that confers PARP Inhibitor Sensitivity

Presenter:          Dr. Ranjit Bindra

Session:               Advances in Clinical Biomarker Development

Date/Time:         Thursday, January 31^st from 2:00 – 2:30 p.m. EST

Per Hellsund, President and CEO of Cybrexa, commented, “At Cybrexa, our mission is to develop new treatment options for patient populations with high unmet need. Based on preclinical data, we believe our alphalex™ technology will be able to successfully combine a potent PARP inhibitor with chemotherapy to enable more efficacious therapeutic combinations in new patient populations. To that end, we are very excited to share the potential of our technology at the upcoming DNA Damage Response Therapeutics Summit.”

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at www.cybrexa.com.

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

Contacts

Media Relations

[email protected]